Trial Profile

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Personalised cancer therapy-BriaCell Therapeutics (Primary) ; Tislelizumab (Primary) ; Cyclophosphamide; Peginterferon alfa-2a
Indications Advanced breast cancer; Cancer metastases; HER2 negative breast cancer
Focus Adverse reactions; First in man; Proof of concept
Acronyms Bria-OTS
Sponsors BriaCell Therapeutics Corp

Most Recent Events

14 Feb 2026 According to BriaCell Therapeutics Corp media release, The Phase 1 dose escalation portion of the study is complete and the Phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor, is now underway.
13 Jan 2026 Results published in the Media Release
09 Jul 2025 According to BriaCell Therapeutics Corp media release, the patient has been dosed with 12 cycles of Bria-OTS to date.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com